Revolution Medicines Inc
NASDAQ:RVMD
Relative Value
The Relative Value of one RVMD stock under the Base Case scenario is 1.05 USD. Compared to the current market price of 35.96 USD, Revolution Medicines Inc is Overvalued by 97%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
RVMD Competitors Multiples
Revolution Medicines Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Revolution Medicines Inc
NASDAQ:RVMD
|
5.9B USD | 511.4 | -13.6 | -8.5 | -8.4 | ||
US |
Abbvie Inc
NYSE:ABBV
|
281.9B USD | 5.2 | 58.5 | 12.7 | 19.4 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
146.2B USD | 5.2 | 21.8 | 16.2 | 24.3 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102B USD | 10.3 | 28.2 | 22.5 | 23.6 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
97.7B USD | 7.5 | 24.7 | 16.3 | 18 | ||
AU |
CSL Ltd
ASX:CSL
|
132.9B AUD | 6.1 | 35.1 | 21.3 | 26.4 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
82.9B USD | 3.1 | 14.6 | 8 | 10.3 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
42.4B USD | 6.2 | -9 | -9.5 | -8.1 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.6B USD | 3.2 | 27.2 | 14.7 | 18.2 | ||
KR |
Celltrion Inc
KRX:068270
|
38.1T KRW | 17.5 | 71.1 | 43.5 | 59.9 |